Jeffery C H Chan, Eugene Yu-Hin Chan, Samuel M S Cheng, Daniel Leung, Fanny Tsz-Wai Ho, Pak-Chiu Tong, Wai-Ming Lai, Matthew H L Lee, Stella Chim, Leo C H Tsang, Tsz-Chun Kwan, Yin Celeste Cheuk, Manni Wang, Howard H W Wong, Amos M T Lee, Wing Yan Li, Sau Man Chan, Issan Y S Tam, Jennifer H Y Lam, Kaiyue Zhang, Wenwei Tu, Malik Peiris, Jaime S Rosa Duque, Yu Lung Lau, Alison Lap-Tak Ma
{"title":"Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases.","authors":"Jeffery C H Chan, Eugene Yu-Hin Chan, Samuel M S Cheng, Daniel Leung, Fanny Tsz-Wai Ho, Pak-Chiu Tong, Wai-Ming Lai, Matthew H L Lee, Stella Chim, Leo C H Tsang, Tsz-Chun Kwan, Yin Celeste Cheuk, Manni Wang, Howard H W Wong, Amos M T Lee, Wing Yan Li, Sau Man Chan, Issan Y S Tam, Jennifer H Y Lam, Kaiyue Zhang, Wenwei Tu, Malik Peiris, Jaime S Rosa Duque, Yu Lung Lau, Alison Lap-Tak Ma","doi":"10.1093/ckj/sfaf052","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Children with chronic kidney disease (CKD) are at risk of severe complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and are recommended to receive vaccine boosters. Although coronavirus disease 2019 (COVID-19) boosters are effective in providing immune responses among healthy children, data on the use of a fourth dose among children with CKD are limited.</p><p><strong>Methods: </strong>We prospectively investigated the immunogenicity and safety of a fourth dose of BNT162b2 in children with CKD. Dosages were 0.1 mL and 0.3 mL for children aged 5-11 years and 11-18 years, respectively. Humoral and cellular immunogenicity was assessed at pre-dose 4, and at 1 and 6 months post-dose 4.</p><p><strong>Results: </strong>Twenty-one children, with a median age of 14.0 years, were included for evaluation. A fourth dose of BNT162b2 elicited significant increases in humoral spike receptor-binding domain immunoglobulin G levels and T-cell responses. Antibody responses were significantly lower among kidney transplant recipients or children receiving calcineurin inhibitors than other CKD children at 1 month post-dose 4. Breakthrough COVID-19 occurred in three children after the fourth dose, and one was hospitalized. One child developed mild gross hematuria 1 day after the fourth dose, which spontaneously resolved. The overall safety profile was acceptable.</p><p><strong>Conclusions: </strong>A fourth dose of BNT162b2 was immunogenic and safe in children with CKD.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 3","pages":"sfaf052"},"PeriodicalIF":3.9000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926591/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Kidney Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ckj/sfaf052","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Children with chronic kidney disease (CKD) are at risk of severe complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and are recommended to receive vaccine boosters. Although coronavirus disease 2019 (COVID-19) boosters are effective in providing immune responses among healthy children, data on the use of a fourth dose among children with CKD are limited.
Methods: We prospectively investigated the immunogenicity and safety of a fourth dose of BNT162b2 in children with CKD. Dosages were 0.1 mL and 0.3 mL for children aged 5-11 years and 11-18 years, respectively. Humoral and cellular immunogenicity was assessed at pre-dose 4, and at 1 and 6 months post-dose 4.
Results: Twenty-one children, with a median age of 14.0 years, were included for evaluation. A fourth dose of BNT162b2 elicited significant increases in humoral spike receptor-binding domain immunoglobulin G levels and T-cell responses. Antibody responses were significantly lower among kidney transplant recipients or children receiving calcineurin inhibitors than other CKD children at 1 month post-dose 4. Breakthrough COVID-19 occurred in three children after the fourth dose, and one was hospitalized. One child developed mild gross hematuria 1 day after the fourth dose, which spontaneously resolved. The overall safety profile was acceptable.
Conclusions: A fourth dose of BNT162b2 was immunogenic and safe in children with CKD.
期刊介绍：
About the Journal
Clinical Kidney Journal: Clinical and Translational Nephrology (ckj), an official journal of the ERA-EDTA (European Renal Association-European Dialysis and Transplant Association), is a fully open access, online only journal publishing bimonthly. The journal is an essential educational and training resource integrating clinical, translational and educational research into clinical practice. ckj aims to contribute to a translational research culture among nephrologists and kidney pathologists that helps close the gap between basic researchers and practicing clinicians and promote sorely needed innovation in the Nephrology field. All research articles in this journal have undergone peer review.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
